Alecensa (alectinib) Disease Interactions
There are 5 disease interactions with Alecensa (alectinib):
Alectinib (Includes Alecensa) ↔ bradycardia
Moderate Potential Hazard, Moderate plausibility. Applies to: Arrhythmias
Cases of bradycardia have been reported in patients treated with alectinib. It is recommended to monitor heart rate and blood pressure regularly. Dose modification is not required in cases of asymptomatic bradycardia. In cases of symptomatic bradycardia that is not life-threatening, withhold therapy until recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above and evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If attributable to a concomitant medication, resume alectinib at a reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above, with frequent monitoring as clinically indicated. Permanently discontinue alectinib in case of recurrence. Permanently discontinue alectinib in cases of life-threatening bradycardia if no contributing concomitant medication is identified.
Alectinib (Includes Alecensa) ↔ hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease
No dose adjustment is recommended for patients with mild hepatic impairment. It is recommended to monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. It might be necessary to withhold therapy and resume at a reduced dose, or permanently discontinue treatment based on the severity of the adverse events. Care should be exercised when using alectinib in patients with moderate or severe hepatic impairment as its safety has not been studied in these patients.
Alectinib (Includes Alecensa) ↔ myalgia
Moderate Potential Hazard, Moderate plausibility. Applies to: Myopathy
Elevations of Creatine Phosphokinase (CPK) have been reported with the use of alectinib. It is recommended to watch closely for signs and symptoms of CPK elevation and to advise patients to report any unexplained muscle pain, tenderness, or weakness. Assess CPK levels regularly as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, withhold therapy and then resume or reduce dose.
Alectinib (Includes Alecensa) ↔ renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
No dose adjustment is recommended for patients with mild or moderate renal impairment. Care should be exercised when using alectinib in patients with severe renal impairment or end-stage renal disease as its safety has not been studied in these patients.
Multikinase inhibitors (Includes Alecensa) ↔ lung toxicity
Moderate Potential Hazard, Moderate plausibility. Applies to: Interstitial Pneumonitis, Pulmonary Impairment
The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures. Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.
Alecensa (alectinib) drug interactions
There are 104 drug interactions with Alecensa (alectinib)
Alecensa (alectinib) alcohol/food interactions
There is 1 alcohol/food interaction with Alecensa (alectinib)
More about Alecensa (alectinib)
- Alecensa Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: multikinase inhibitors
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.